Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Citalopram. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 15/20 | 0.90 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.90 |
| ▸ | LMNA | P02545 | 1/20 | 0.90 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.85 |
| ▸ | HTR2C | P28335 | 2/20 | 0.85 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.85 |
| ▸ | HRH1 | P35367 | 2/20 | 0.85 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.85 |
| ▸ | DRD3 | P35462 | 2/20 | 0.85 |
| ▸ | HTR2B | P41595 | 2/20 | 0.85 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.85 |
| ▸ | NPC1 | O15118 | 1/20 | 0.85 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.85 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.85 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.85 |
| ▸ | HTR1A | P08908 | 1/20 | 0.85 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.85 |
| ▸ | DRD1 | P21728 | 1/20 | 0.85 |
| ▸ | ACHE | P22303 | 1/20 | 0.85 |
| ▸ | HRH2 | P25021 | 1/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Escitalopram SCHEMBL28980945 | 0.95 | SLC6A4 (0.94) | SLC6A4MAPK1LMNASLC6A2HTR2C | |
| Escitalopram SCHEMBL28631467 | 0.95 | SLC6A4 (0.94) | SLC6A4MAPK1LMNASLC6A2HTR2C | |
| Citalopram SCHEMBL28369040 | 0.94 | SLC6A4 (1.00) | SLC6A4MAPK1LMNASLC6A2HTR2C | |
| Citalopram SCHEMBL2010566 | 0.94 | SLC6A4 (1.00) | SLC6A4MAPK1LMNASLC6A2HTR2C | |
| Escitalopram SCHEMBL35123 | 0.94 | SLC6A4 (1.00) | SLC6A4MAPK1LMNASLC6A2HTR2C | |
| Citalopram SCHEMBL29604018 | 0.94 | SLC6A4 (1.00) | SLC6A4MAPK1LMNASLC6A2HTR2C | |
| Escitalopram SCHEMBL27936829 | 0.94 | SLC6A4 (1.00) | SLC6A4MAPK1LMNASLC6A2HTR2C | |
| Escitalopram SCHEMBL30223023 | 0.94 | SLC6A4 (1.00) | SLC6A4MAPK1LMNASLC6A2HTR2C | |
| Escitalopram SCHEMBL34948 | 0.92 | SLC6A4 (1.00) | SLC6A4MAPK1LMNASLC6A2HTR2C | |
| Citalopram SCHEMBL946 | 0.92 | SLC6A4 (1.00) | SLC6A4MAPK1LMNASLC6A2HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1720541-A1 | TREATMENT OR PROPHYLAXIS OF MIGRAINE OR HEADACHE DISORDERS USING CITALOPRAM, ESCITALOPRAM OR CITALOPRAM METABOLITES | Sepracor, Inc. (US) | 2006-11-15 | — | — | EP | claimed |
| US-20050192344-A1 | Treatment or prophylaxis of migraine or headache disorders using citalopram, escitalopram or citalopram metabolites | SEPRACOR INC. (US) | 2005-09-01 | — | — | US | claimed |
| WO-2005079787-A1 | TREATMENT OR PROPHYLAXIS OF MIGRAINE OR HEADACHE DISORDERS USING CITALOPRAM, ESCITALOPRAM OR CITALOPRAM METABOLITES | SEPRACOR INC. (US) | 2005-09-01 | — | — | WO | claimed |
| US-11894139-B1 | Disease spectrum classification | PATIENTSLIKEME LLC (US) | 2024-02-06 | — | — | US | disclosed |
| US-7714023-B2 | Treatment or prophylaxis of migraine or headache disorders using citalopram, escitalopram or citalopram metabolites | SEPRACOR INC. (US) | 2010-05-11 | — | — | US | disclosed |
| EP-1720541-A1 | TREATMENT OR PROPHYLAXIS OF MIGRAINE OR HEADACHE DISORDERS USING CITALOPRAM, ESCITALOPRAM OR CITALOPRAM METABOLITES | Sepracor, Inc. (US) | 2006-11-15 | — | — | EP | disclosed |
| US-20050192344-A1 | Treatment or prophylaxis of migraine or headache disorders using citalopram, escitalopram or citalopram metabolites | SEPRACOR INC. (US) | 2005-09-01 | — | — | US | disclosed |
| WO-2005079787-A1 | TREATMENT OR PROPHYLAXIS OF MIGRAINE OR HEADACHE DISORDERS USING CITALOPRAM, ESCITALOPRAM OR CITALOPRAM METABOLITES | SEPRACOR INC. (US) | 2005-09-01 | — | — | WO | disclosed |
| US-20040266864-A1 | Methods for treating depression and other CNS disorders using enantiomerically enriched desmethyl-and didesmethyl-metabolites of citalopram | SEPRACOR INC. | 2004-12-30 | — | — | US | disclosed |
| EP-1446396-A1 | METHODS FOR TREATING DEPRESSION AND OTHER CNS DISORDERS USING ENANTIOMERICALLY ENRICHED DESMETHYL- AND DIDESMETHYL-METABOLITES OF CITALOPRAM | Sepracor, Inc. (US) | 2004-08-18 | — | — | EP | disclosed |
| WO-2003040121-A1 | METHODS FOR TREATING DEPRESSION AND OTHER CNS DISORDERS USING ENANTIOMERICALLY ENRICHED DESMETHYL- AND DIDESMETHYL-METABOLITES OF CITALOPRAM | SEPRACOR, INC. (US) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192344-A1 | Treatment or prophylaxis of migraine or headache disorders using citalopram, escitalopram or citalopram metabolites | SLC6A4, HTR4, HTR1A | SLC6A4 1/4885MAPK1 3128/4885LMNA 888/4885 |
| US-20040266864-A1 | Methods for treating depression and other CNS disorders using enantiomerically enriched desmethyl-and didesmethyl-metabolites of citalopram | PNMT, SLC6A2, SLC6A3 | SLC6A4 4/4885MAPK1 3707/4885LMNA 2968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.